TFF Pharmaceuticals, Inc. (TFFP)
NASDAQ: TFFP · IEX Real-Time Price · USD
1.780
0.00 (0.00%)
At close: Jul 2, 2024, 4:00 PM
1.760
-0.020 (-1.12%)
After-hours: Jul 2, 2024, 7:54 PM EDT
TFF Pharmaceuticals Revenue
TFF Pharmaceuticals had revenue of $885.72K in the twelve months ending March 31, 2024, with 84.60% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $203.27K with 295.25% year-over-year growth. In the year 2023, TFF Pharmaceuticals had annual revenue of $733.87K with 48.02% growth.
Revenue (ttm)
$885.72K
Revenue Growth
+84.60%
P/S Ratio
6.23
Revenue / Employee
$46,617
Employees
19
Market Cap
5.51M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 733.87K | 238.07K | 48.02% |
Dec 31, 2022 | 495.81K | 407.64K | 462.39% |
Dec 31, 2021 | 88.16K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTFFP News
- 6 days ago - TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities - GlobeNewsWire
- 5 weeks ago - TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing - GlobeNewsWire
- 6 weeks ago - TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing - GlobeNewsWire
- 6 weeks ago - TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection - GlobeNewsWire
- 7 weeks ago - TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting - GlobeNewsWire